In this review:
Will surgery be included in future treatment of BC?
New developments in surgery for early-stage BC
Cancer outcomes & toxicity with new RT techniques & regimens
Omission of RT in older patients with small ER+ tumours
New developments in systemic therapy
Risk assessment of late recurrence from ER+ BC
Heterogeneity in treatment response in TNBC
Bone-targeted treatments in the adjuvant setting
Patient satisfaction with scalp cooling
Neoadjuvant talazoparib in TNBC with germline BRCA1/2 mutations
Neratinib in HR+ BC after trastuzumab-based adjuvant therapy
Please login below to download this issue (PDF)